Compare DuPont de Nemours Inc (DD) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs IDEXX Laboratories, Inc. — how do they compare? DuPont de Nemours Inc trades at $130.25 (market cap $17.89B), while IDEXX Laboratories, Inc. trades at $517.55 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.3× DuPont de Nemours Inc's market cap, and DuPont de Nemours Inc pays a 1.81% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DuPont de Nemours Inc for 89 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| DD | IDXX | |
|---|---|---|
Market Cap | $17.89B | $40.43B |
Volume | 816,409 | 692,164 |
Sector | Basic Materials | Health |
52-Week High | $154.59 | $766.68 |
52-Week Low | $92.49 | $504.70 |
Typical Hold Time | 89 Days | 46 Days |
Enterprise Value | $19.28B | $41.32B |
Dividend Yield | 1.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $131.08, down 1.65% on the day, with a neutral technical signal and mixed fundamentals. Recent earnings have consistently beaten estimates, but 2025 saw a net loss of $779 million on revenue of $6.85 billion. The company maintains innovation with new product launches like the Sugar Separation Advisor and Tyvek with Renewable Attribution, while facing headwinds from legal settlements and uneven demand.
The outlook is cautious; analyst consensus is bullish with a 58.54% buy rating but a price target of $95.00 below the current price. Key opportunities include margin expansion in growth markets, while risks involve PFAS litigation costs, volatile cash flows, and execution challenges in a competitive landscape.
IDEXX Laboratories (IDXX) trades at $517.47, up 2.13% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and expanded diagnostic platforms highlight growth initiatives, while analyst consensus remains bullish with a $665 price target representing 28.5% upside potential.
The outlook remains positive given consistent earnings beats and expanding veterinary diagnostics market share. Key risks include FX headwinds, weaker U.S. vet visits, and premium valuations at 36x P/E. Institutional ownership trends show mixed activity with recent insider selling, but long-term growth drivers in pet healthcare innovation support the bullish analyst stance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
